A Multicenter, Randomized, Open-label, Blinded-assessor, Phase 4 Study in Patients With Early Rheumatoid Arthritis to Compare Active Conventional Therapy Versus Three Biologic Treatments, and Two De-escalation Strategies in Patients Who Respond to Treatment.

Trial Profile

A Multicenter, Randomized, Open-label, Blinded-assessor, Phase 4 Study in Patients With Early Rheumatoid Arthritis to Compare Active Conventional Therapy Versus Three Biologic Treatments, and Two De-escalation Strategies in Patients Who Respond to Treatment.

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 12 Jul 2017

At a glance

  • Drugs Abatacept (Primary) ; Certolizumab pegol (Primary) ; Tocilizumab (Primary) ; Azathioprine; Corticosteroids; Hydroxychloroquine; Methotrexate; Sulfasalazine
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms NORD-STAR
  • Most Recent Events

    • 07 Jun 2017 Planned End Date changed from 1 Dec 2020 to 1 Dec 2021.
    • 07 Jun 2017 Planned primary completion date changed from 1 Dec 2020 to 1 Mar 2019.
    • 01 Dec 2015 Planned End Date changed from 1 Dec 2018 to 1 Dec 2020, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top